索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Gene Therapy that for the Treatment of Sickle cell Anemia

Mrunalini Deosthale

Quality treatment could give a fix to a lot more individuals since it doesn't depend on a benefactor: all things being equal, immature microorganisms are reaped from the patient's own bone marrow. As a further advantage, quality treatment evades strife between the contributor's and beneficiary's cells. After a bone-marrow relocate, specialists need to smother the beneficiary's resistant framework to keep it from assaulting the transfer, which leaves the patient helpless against disease. And still, at the end of the day, the benefactor cells may assault the beneficiary's cells, bringing about unite versus-have illness — the main source of death after a bone-marrow relocate. Quality treatment wipes out this worry

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证